ML Montesinos CV

1) Academic career:


• Grade in Biology with Special Awards. July 1992. Universidad de Sevilla (Spain).

• PhD cum laude in Biology (Biochemistry and Molecular Biology). October 1997.

Instituto de Bioquímica Vegetal y Fotosíntesis (CSIC-Universidad de Sevilla).

Subject: Amino acid, ammonium and urea transport systems in cyanobacteria.

Supervisors: Enrique Flores and Antonia Herrero.


2) Professional career:


• November 1997 to September 2003: Postdoctoral Researcher. Ecole Normale Supérieure-CNRS. Alain Prochiantz’s lab (Paris, France).

Positions during that period: Postdoctoral EMBO fellow (1997/99). Associate Researcher CR3 (funded by CNRS, 1999/2000). Postdoctoral fellow from FRM (“Foundation pour la Recherche Medicale”, 2001/01). Assistant Professor (ATER) of Molecular and Cellular Genetics (2001/02). Associate Researcher (funded by Human Frontier Science Program, 2002/03).

Subjects:

-Target genes, cofactors and mode of action of Engrailed homeoproteins during vertebrate CNS development.

-Engrailed-1 homeoprotein: dendritic localization and role in local translation.


• October 2003 to December 2005: “Ramón y Cajal” Investigator, associated to Rafael Fernández-Chacón’s lab. Dpto. Fisiología Médica y Biofísica. Universidad de Sevilla (Spain).

Subject: synaptic proteins involved in neurodegeneration.


• January 2006 to date: Synaptic local translation laboratory Group leader. Dpto. Fisiología Médica y Biofísica. University of Seville.

Positions during that period: “Ramón y Cajal” Investigator until February 2008. From March 2008 to date, Associate Professor of Physiology.

Subject: mRNA transport and local translation in synaptic pathologies.

Research Group affiliated to IBiS (Instituto de Biomedicina de Sevilla).


3) General administrative and organizational experience


• Sociedad Española de NeuroCiencia (SENC) Executive Board member (October 2013 to September 2017).

• Chair of the SENC Communication Committee (October 2013 to September 2017).

• FENS Communication Committee member (July 2014 to July 2018).

• Sociedad Española de Bioquímica y Biología Molecular (SEBBM) Molecular Neurobiology Group Coordinator (October 2015 to July 2019).

• Chair of the Trisomy 21 Research Society (T21RS) Communication Work Group (June 2018-October 2020).

• Academic administrative responsibility as Secretary of the Departmento de Fisiología Médica y Biofísica (Universidad de Sevilla, Spain). February 2010-February 2013.



SOME SELECTED PUBLICATIONS


1) JD Urbano-Gámez, JJ Casañas, I Benito, ML Montesinos

Prenatal treatment with rapamycin restores enhanced hippocampal mGluR-LTD and mushroom spine size in a Down's syndrome mouse model

Mol Brain 18:84 (2021)

Open access: https://rdcu.be/cljMb


    2) JJ. Casañas, M. González-Corrales, JD. Urbano-Gámez, A. Alvez-Sampaio, JA. Troca-Marín, ML. Montesinos

    CPEB1 is overexpressed in neurons derived from Down syndrome IPSCs and in the hippocampus of the mouse model Ts1Cje

    Mol Cell Neurosci 95: 79-89 (2019)


    3) I. Benito, JJ. Casañas, ML. Montesinos

    Proteomic analysis of synaptoneurosomes highlights the relevant role of local translation in the hippocampus

    Proteomics 18:e1800005 (2018)


    4) Y. Andrade-Talavera, I. Benito, JJ. Casañas, A. Rodríguez-Moreno, ML. Montesinos

    Rapamycin restores BDNF-LTP and the persistence of long-term memory in a model of Down's syndrome

    Neurobiol. Dis. 82:516-525 (2015)


    5) JA. Troca-Marín, JJ. Casañas, I. Benito, ML. Montesinos

    The Akt-mTOR pathway in Down's syndrome: the potential use of rapamycin/rapalogs for treating cognitive deficits

    CNS Neurol. Disord. Drug Targets 13:34-40 (2014)


    6) JA. Troca-Marín, A. Alves-Sampaio, ML. Montesinos

    Deregulated mTOR-mediated translation in intellectual disability

    Prog. Neurobiol. 96:268-282 (2012)


    7) JA. Troca-Marín, A. Alves-Sampaio, ML. Montesinos

    An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down’s syndrome

    J. Neurosci. 31:9445-9455 (2011)


    8) A. Alves-Sampaio, JA. Troca-Marín and ML. Montesinos

    NMDA-mediated regulation of DSCAM dendritic local translation is lost in a mouse model of Down's syndrome

    J. Neurosci. 30: 13537-13548 (2010)


    9) JA. Troca-Marín, A. Alves-Sampaio, FJ. Tejedor and ML. Montesinos

    Local translation of dendritic RhoA revealed by an improved synaptoneurosome preparation

    Mol. Cell. Neurosci. 43:308-315 (2010)


    10) A. Di Nardo, S. Nedelec, A. Trembleau, M. Volovitch, A. Prochiantz and ML. Montesinos

    Dendritic localization and activity-dependent translation of Engrailed1 transcription factor

    Mol. Cell. Neurosci. 35:230-236 (2007)


    11) ML. Montesinos, M. Castellano-Muñoz, P. García-Junco-Clemente and R. Fernández-Chacón

    Recycling and EH-domain proteins at the synapse

    Brain Res. Rev. 49:416-428 (2005)


    12) R. Fernández-Chacón, M. Wölfel, H. Nishimune, L. Tabares, F. Schmitz, M. Castellano-Muñoz, C. Rosenmund, ML. Montesinos, JR. Sanes, R. Schneggenburger and TC. Südhof

    The synaptic vesicle protein CSP-alpha prevents presynaptic degeneration

    Neuron 42:237-251 (2004)


    13) I. Foucher, ML. Montesinos, M. Volovitch, A. Prochiantz and A. Trembleau

    Joint regulation of the MAP1B promoter by HNF3ß/Foxa2 and Engrailed is the result of a highly conserved mechanism for direct interaction of homeoproteins and Fox transcription factors

    Development 130:1867-1876 (2003)


    14) ML. Montesinos, I. Foucher, M. Conradt, G. Mainguy, L. Robel, A. Prochiantz and M. Volovitch

    The neuronal Microtubule-Associated Protein 1B (MAP1B) is under homeoprotein transcriptional control

    J. Neurosci. 21:3350-3359 (2001)


    15) G. Mainguy, ML. Montesinos, B. Lesaffre, B. Zevnik, M. Karasawa, R. Kothary, W. Wurst, A. Prochiantz and M. Volovitch

    An induction gene trap for indentifying a homeoprotein-regulated locus

    Nat. Biotechnol. 18:746-749 (2000)

    Highlighted in “This month in Nature Biotechnology”